Cangrelor is a fast and directly acting platelet aggregation inhibitor. It is potentially indicated for several types of patients who are undergoing PCI. A nationwide cangrelor registry has up until now not been performed. The “Dutch Cangrelor Registry” aims to investigate the efficacy and safety of cangrelor in the Netherlands.

Primary endpoint is a 48 hours Net Adverse Clinical Events, which is a composite endpoint of all cause death (including cardiac death), recurrent myocardial infarction, target vessel revascularization, definite or probable stent thrombosis, stroke and bleeding (BARC type 2-5).

The Dutch Cangrelor Registry is a multicenter non-interventional prospective registry aiming to include 250 patients in 8 centres in The Netherlands.

The first patient was included in December 2019 in the Isala hospital in the Netherlands.

Clinical investigators

Principal investigator:
Name: Rik Hermanides MD, PhD (intervention cardiologist)
Location: Isala, Zwolle

Co-principal investigators:
Name: Prof. Arnoud van ’t Hof MD PhD (intervention cardiologist)
Location: Maastricht UMC+ and Zuyderland, Heerlen

Name: Prof. Jur ten Berg MD, PhD (intervention cardiologist)
Location: St. Antonius Ziekenhuis, Nieuwegein

Clinical trial information

Check a full summary about this clinical trial here.
Or contact for more information.

Main publications

Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: the Dutch Cangrelor registry. European Heart Journal Open, Volume 1, Issue 3, November 2021.

Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry. BMC Cardiovasc Disord. 2021 Jun 12;21(1):292.